Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00733408
Title Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

breast cancer

Therapies

Bevacizumab + Erlotinib + Nab-paclitaxel

Age Groups: adult
Covered Countries USA


No variant requirements are available.